An investigation of human and rat liver microsomal mycophenolic acid glucuronidation: Evidence for a principal role of UGT1A enzymes and species differences in UGT1A specificity

被引:55
作者
Miles, KK
Stern, ST
Smith, PC
Kessler, FK
Ali, S
Ritter, JK
机构
[1] Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Sch Med, Richmond, VA 23298 USA
[2] Univ N Carolina, Sch Pharm, Div Drug Delivery & Disposit, Chapel Hill, NC USA
关键词
D O I
10.1124/dmd.105.004663
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Mycophenolic acid (MPA; 1,3-dihydro-4-hydroxy-6-methoxy-7-methyl- 3-oxo-5-isobenzylfuranyl)-4-methyl-4-hexenoate), the active metabolite of the immunosuppressant prodrug, mycophenolate mofetil, undergoes glucuronidation to its 7-O-glucuronide as a primary route of metabolism. Because differences in glucuronidation may influence the efficacy and/or toxicity of MPA, we investigated the MPA UDP-glucuronosyltransferase (UGT) activities of human liver microsomes (HLMs) and rat liver microsomes with the goal of identifying UGTs responsible for MPA catalysis. HLMs ( n = 23) exhibited higher average MPA glucuronidation rates (14.7 versus 6.0 nmol/mg/min, respectively, p < 0.001) and higher apparent affinity for MPA ( K-m = 0.082 mM versus 0.20 mM, p < 0.001) compared with rat liver microsomes. MPA UGT activities were reduced > 80% in liver microsomes from Gunn rats. To identify the active enzymes, human and rat UGT1A enzymes were screened for MPA-glucuronidating activity. UGT1A9 was the only human liver-expressed UGT1A enzyme with significant activity and exhibited both high affinity (K-m = 0.077 mM) and high activity (V-max = 28 nmol center dot min(-1) center dot mg(-1)). Spearman correlation analyses revealed a stronger relationship between HLM MPA UGT activities and 1A9-like content (r(2) = 0.79) relative to 1A1 (r(2) = 0.20), 1A4-like (r(2) = 0.22), and 1A6 (r(2) = 0.41) protein. A different profile was observed for rat with three active liver-expressed UGT1A enzymes: 1A1 ( medium affinity/capacity), 1A6 ( low affinity/medium capacity), and 1A7 ( high affinity/capacity). Our data suggest that UGT1A enzymes are the major contributors to hepatic MPA metabolism in both species, but 1A9 is dominant in human, whereas 1A1 and 1A7 are likely the principal mediators in control rat liver. This information should be useful for interpretation of MPA pharmacokinetic and toxicity data in clinical and animal studies.
引用
收藏
页码:1513 / 1520
页数:8
相关论文
共 25 条
[11]   Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid [J].
Mackenzie, PI .
THERAPEUTIC DRUG MONITORING, 2000, 22 (01) :10-13
[12]   The use of mycophenolate mofetil in transplant recipients [J].
Mele, TS ;
Halloran, PF .
IMMUNOPHARMACOLOGY, 2000, 47 (2-3) :215-245
[13]   The human UDP glucuronosyltransferase, UGT1A10, glucuronidates mycophenolic acid [J].
Mojarrabi, B ;
Mackenzie, PI .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 238 (03) :775-778
[14]  
Mourad M, 2001, CLIN CHEM, V47, P88
[15]   Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism [J].
Picard, N ;
Ratanasavanh, D ;
Prémaud, A ;
Le Meur, Y ;
Marquet, P .
DRUG METABOLISM AND DISPOSITION, 2005, 33 (01) :139-146
[16]   Expression and inducibility of the human bilirubin UDP-glucuronosyltransferase UGTLA1 in liver and cultured primary hepatocytes: Evidence for both genetic and environmental influences [J].
Ritter, JK ;
Kessler, FK ;
Thompson, ET ;
Grove, AD ;
Auyeung, DJ ;
Fisher, RA .
HEPATOLOGY, 1999, 30 (02) :476-484
[17]   2 HUMAN LIVER CDNAS ENCODE UDP-GLUCURONOSYLTRANSFERASES WITH 2 LOG DIFFERENCES IN ACTIVITY TOWARD PARALLEL SUBSTRATES INCLUDING HYODEOXYCHOLIC ACID AND CERTAIN ESTROGEN DERIVATIVES [J].
RITTER, JK ;
CHEN, F ;
SHEEN, YY ;
LUBET, RA ;
OWENS, IS .
BIOCHEMISTRY, 1992, 31 (13) :3409-3414
[18]   MYCOPHENOLIC-ACID - MEASUREMENT AND RELATIONSHIP TO PHARMACOLOGICAL EFFECTS [J].
SHAW, LM ;
NOWAK, I .
THERAPEUTIC DRUG MONITORING, 1995, 17 (06) :685-689
[19]   Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes [J].
Shipkova, M ;
Strassburg, CP ;
Braun, F ;
Streit, F ;
Gröne, HJ ;
Armstrong, VW ;
Tukey, RH ;
Oellerich, M ;
Wieland, E .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 132 (05) :1027-1034
[20]   The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors [J].
Sintchak, MD ;
Nimmesgern, E .
IMMUNOPHARMACOLOGY, 2000, 47 (2-3) :163-184